For decades, skincare has been driven by claims, trends, and trial-and-error. But what if we could actually measure how products impact the skin at the microbial and molecular level?
That’s exactly what our SOSV portfolio company Sequential is doing.
With a fresh $3.5 million Seed co-led by Sparkfood and Corundum Systems Biology (CSB), with participation from SOSV, Dermazone Holdings, Scrum Ventures, and Innovate UK, they are using a proprietary, non-invasive testing platform that quantifies how ingredients and products (from consumer skincare to biotech and pharma) affect both the skin microbiome and host biomarkers. The result: clear, actionable insights that enable brands to build products that are not just marketable, but scientifically credible and effective.
Already working with 100+ paying customers, including Johnson & Johnson, Sequential has built one of the most comprehensive clinical datasets in the industry, comprising over 50,000 samples, 4,000+ ingredients, and 10,000+ participants worldwide.
Now, they’re taking it a step further: developing an AI-powered discovery engine enabling the predict, discover, and optimize the next-generation active complexes and novel bioactive ingredients.
Uncategorized,biomarkers,consumer,skincare,skinhealthbiomarkers,consumer,skincare,skinhealth#Sequential #Raises #3.5M #Build #AIPowered #Discovery #Platform #MultiOmic #Testing #amp #Skin #Health #Ingredients1774030659
